Navigation Links
InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
Date:10/16/2008

o announce top-line efficacy and safety results in January or February of 2009, and remains on track for submission of a New Drug Application (NDA) in mid-2009, pending positive data from CAPACITY. Pirfenidone has received Fast Track designation from the FDA, and if granted Priority Review status, InterMune could receive a six-month review of its NDA submission.

Mr. Welch added, "As we approach the last patient visits in our two CAPACITY studies, we are extremely pleased with the quality of the study conduct and to have exceeded our aggressive goal for having at least 95% of transplant-free, surviving patients reporting for their Week 72 Visit. We look forward to reporting top-line results of CAPACITY in January or in February of 2009."

Pirfenidone has been granted Orphan Drug and Fast Track designation in the United States and Orphan Drug designation in Europe for the treatment of IPF.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a disabling and ultimately fatal disease that affects a total of approximately 200,000 people in the United States and Europe, with approximately 30,000 new cases developing in the United States alone, each year. There are no medicines approved by the U.S. Food and Drug Administration (FDA) or European Medicines Evaluation Agency (EMEA) for the treatment of IPF. IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough. IPF is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is two to five years.

About Pirfenidone

Prior in-vitro evidence has shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferation. Data presented from one Phase 3 study and four Phase 2 clinical trials in more than 400 patients suggest that pirfenidone may positively
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Scientific Corporation (NYSE: BSX ) today announced ... aggregate principal amount of its senior notes under the ... of $850 million of 4.50 percent notes due January ... 2020 and $300 million of 7.375 percent notes due ... net proceeds for general corporate purposes, including prepaying its ...
(Date:12/14/2009)... has completed the delivery of Brookfield Engineering’s Powder Flow Tester ... enclosure with a smaller footprint and more compact design. ... ... 2009 -- ThermoFab, a US-based thermoforming company, has completed the ... move from sheet metal to a plastic enclosure with a ...
(Date:12/11/2009)... December 10, 2009 miRagen Therapeutics, Inc., a ... developing innovative microRNA-based therapeutics for cardiovascular and muscle ... that microRNA-206 (miR-206) plays a crucial role in ... Lou Gehrig,s disease) and in neuromuscular synaptic regeneration ... December 11 issue of the journal Science ...
(Date:12/11/2009)... OSLO, December 11 Algeta ASA ... the first clinical center in the,US, the ... randomizing patients,in the phase III clinical study ... as hormone-refractory) prostate cancer,(CRPC) that has metastasized ... The ALSYMPCA (ALpharadin in SYMptomatic Prostate ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... change as a result of the Sarbanes-Oxley Act ... and companies to continually evaluate their financial controls ... to the technology requirements and information technology (IT) ... technology; however, it is difficult to envision compliance ...
... has an ancient and proud history of interstate sports ... Sometimes, like this past New Years Day, the rivalry ... Wolverines and marijuana have in common? They both get ... be fomenting another interstate rivalry. This one is of ...
... will support American Musical Supplys (AMS) expansion plans ... solutions. AMS , a supplier of musical ... next year and develop business-to-business sales channels using ... , ,AMS was driven to establish a ...
Other Biology Technology:Technology Implications of Sarbanes-Oxley 2Technology Implications of Sarbanes-Oxley 3For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 2For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 3For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 4
(Date:12/13/2009)... Haven, Conn.A team led by Yale University researchers ... whole blood for the first time. Their findings, ... publication of Nature Nanotechnology , could dramatically ... cancer and other diseases. , The ... of Engineering & Applied Science, and Tarek Fahmy, ...
(Date:12/11/2009)... Malus orientalis species of wild apples that could be ... Middle East and Central Asia. A new study comparing ... varieties from Georgia and Armenia with previously collected varieties ... and establishes a core collection that will make ... research communities. , To identify and record the genetic ...
(Date:12/11/2009)... an associate professor of anthropology at the University of ... Kenya to understand how violence shapes the health of ... of her and her colleagues, research," Documenting the health ... northern Kenya: A conceptual framework," is currently published in ... , in collaboration with the British medical journal the ...
Breaking Biology News(10 mins):Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Understanding apples' ancestors 2UA-led study grapples with health effects of low-intensity warfare 2Yoga Can Ease Lower Back Pain 56417 1Yoga Can Ease Lower Back Pain 56417 2Yoga Can Ease Lower Back Pain 56417 3Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 1Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 2Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 3Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 4Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 5Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 6Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 7Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 8K State Veterinarian Says Dog Owners Can Make Themselves Their Pets Healthier With Physical Activity Based on Dogs Specific Needs Interests 56409 1K State Veterinarian Says Dog Owners Can Make Themselves Their Pets Healthier With Physical Activity Based on Dogs Specific Needs Interests 56409 2K State Veterinarian Says Dog Owners Can Make Themselves Their Pets Healthier With Physical Activity Based on Dogs Specific Needs Interests 56409 3K State Veterinarian Says Dog Owners Can Make Themselves Their Pets Healthier With Physical Activity Based on Dogs Specific Needs Interests 56409 4
... have identified, for the first time, a molecule that can ... vital role in gene expression and are closely associated with ... a new generation of cancer drugs. , The research ... a particular miRNA, called miR-21, that is implicated in brain ...
... the AVS 55th International Symposium & Exhibition will showcase ... devoted to discoveries on the edge-in a vacuum, at ... to develop new materials and technologies. , AVS ... come from universities, government agencies, and industrial laboratories alike. ...
... are synthetic hormones derived from the human male hormone ... professional baseball and other sports where building muscle strength, ... a sport. A team of researchers has examined the ... after the athletes had ceased to take the drugs. ...
Other Biology News:Scientists identify novel inhibitor of human microRNA 2Scientists identify novel inhibitor of human microRNA 3Save-the-date: Major nanotech, energy, and biomed meeting 2Save-the-date: Major nanotech, energy, and biomed meeting 3Save-the-date: Major nanotech, energy, and biomed meeting 4Anabolic steroids provide a competitive edge in power lifting years after doping has ended 2Anabolic steroids provide a competitive edge in power lifting years after doping has ended 3
B2-Microgloulin...
Rabbit Anti-Ferret Whole Serum Antibody, Unconjugated...
... priced, full ring small animal imaging PET ... microPET R4 low retail price, it outperfoms ... count rate performance, energy resolution, timing resolution, ... small animal PET (Positron Emission Tomography) imaging ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: